Register for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
Structure TherapeuticsClinical-stage biotech. Lead asset aleniglipron: oral small-molecule GLP-1 agonist. Two positive Phase 2 readouts; high-dose 11%+ placebo-adjusted weight loss at 36 weeks. Roche licensing deal ($100M) for additional assets.
| Trial / Phase | Indication / Dosing | Key Endpoint Result |
|---|---|---|
| Phase 1 SAD/MAD (single/multi ascending dose) | Healthy volunteers + obesity cohort | 2022-2023 readouts; demonstrated dose-related weight reduction + acceptable GI tolerability; supported Phase 2 advancement |
| Phase 2a (GSBR-1290) obesity (12 weeks) | Oral once-daily; up to 120mg | June 2024 topline: 6.2% placebo-adjusted mean weight loss at 12 weeks at the high dose; early proof-of-concept supporting the larger Phase 2b ACCESS program |
| Phase 2b ACCESS core study (obesity, 36 weeks) | Oral once-daily; dose-ranging to 120mg; 230 patients | Dec 2025 topline: 11.3% (27.3 lbs) placebo-adjusted mean weight loss at the 120mg dose at 36 weeks; 10.4% AE-related discontinuation across active arms (mainly GI); supports Phase 3 advancement |
| Phase 2 ACCESS II (obesity, 44 weeks) | Oral once-daily; higher doses (180mg, 240mg) | Mar 16, 2026 topline: 16.3% (39 lbs) placebo-adjusted weight loss at 180mg and 16.0% (37 lbs) at 240mg at 44 weeks; across more than 625 program participants there was no drug-induced liver injury, no persistent liver-enzyme elevations, and no QTc prolongation |
| Type 2 diabetes program | Oral once-daily | A dedicated Type 2 diabetes trial is ongoing; HbA1c and weight-loss endpoints would support a potential T2D label alongside obesity |
| Phase 3 program (planned) | Pivotal obesity registrational | Structure anticipates initiating the aleniglipron Phase 3 program in the second half of 2026, supported by the ACCESS and ACCESS II results |
| Competitive comparison: small molecules vs peptides | Mechanism / format | Small molecule: cheaper to manufacture, standard oral tablet. Peptide: high potency, harder to manufacture, oral formulations need absorption enhancers. Aleniglipron's ACCESS results (11.3% at 36 weeks, up to 16.3% at 44 weeks, placebo-adjusted) are competitive with oral and injectable GLP-1 programs while retaining small-molecule cost advantages |
| Competitive map (oral GLP-1 small molecules) | Other programs in development | LLY orforglipron Phase 3 ahead (2026 launch target); GPCR aleniglipron Phase 3 planned H2 2026; Pfizer danuglipron + lotiglipron discontinued (hepatotoxicity signals, 2023-2025); AstraZeneca AZD5004 Phase 2b; Roche CT-996 Phase 2 (via Carmot acquisition) |
| Editorial. Why GPCR matters | Strategic context | GPCR is the most-credible standalone biotech in the small-molecule oral GLP-1 race. Its ACCESS II result lands GPCR as the #2 oral small-molecule program after LLY orforglipron. The commercial launch is several years out, but acquisition rumors recur (LLY + Pfizer + Roche have all been linked at various points). Most likely outcome: standalone commercial launch or a Big Pharma partnership |
Q3 2022-Q3 2025
2022-2025
$GPCR
Lead asset aleniglipron: oral small-molecule GLP-1 agonist. Two positive Phase 2 readouts; high-dose 11%+ placebo-adjusted weight loss at 36 weeks. Roche licensing deal ($100M) for additional assets signals strategic interest.